Previous investigations of IL13Rα2 as a therapeutic target by various treatment modalities [10,11,33,34] suggest the utility of IL13Rα2 targeting in the context of an immunotherapy or immunoconjugate for multiple diseases, including DIPG. The gene discussed is IL13RA2; the disease is diffuse intrinsic pontine glioma.